Back to mobile site

Goldman Sachs Downgrades Agios Pharma (AGIO) to Sell

July 30, 2021 6:55 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter downgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Sell with a price target of $39.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login